Close

Anti-Peptide INF T cell receptor ((BM3.3)-6), pCDTCR1 (TCR-YC0930)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Consistent with the view that these two polymorphic MHC residues affect peptide-binding preference, identification of the endogenous peptide (pBM8: SQYYYNSL) recognized by the BM3.3 TCR in the context of H-2Kbm8 showed that its anchor residues differed from the ones found in pBM1 and VSV8 sequences. Moreover, further comparison of the pBM8 sequence with that of pBM1 (INFDFNTI) and VSV8 (RGYVYQGL) revealed a single homologous TCR-exposed residue at P6. In contrast, the two other TCR-exposed residues found in the three peptides recognized by BM3.3 showed non-conservative substitutions.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • Peptide INF
  • Epitope
  • INFVFNTI
  • Format
  • Non-Modified TCR
  • Allele
  • H2-Kb
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • BM3.3
  • Host Species
  • Mouse

Target

  • Introduction
  • Many T cell receptors (TCRs) that are selected to respond to foreign peptide antigens bound to self major histocompatibility complex (MHC) molecules are also reactive with allelic variants of self-MHC molecules. This property, termed alloreactivity, causes graft rejection and graft-versus-host disease.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Mouse anti-Peptide INF T cell receptor ((BM3.3)-6), pCDTCR1 (TCR-YC0930). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.